Plerixafor-aided mobilization of peripheral blood hematopoietic stem cells to support subsequent high-dose chemotherapy after a prior autologous transplant

MicroAbstract: Plerixafor, a stem cell mobilizer with proven potential to rescue "poorly" mobilizing patients, was applied after salvage chemotherapy (+G-CSF) in a limited series of patients with potentially curable malignancies, who had relapsed after a previous autograft. This led to successful stem cell mobilization in all patients, who experienced sustained engraftment after further high-dose chemotherapy supported by the plerixafor-mobilized stem cells.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

To investigate the clinical implications of SF3B1 and ring sideroblasts in myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia (MDS-RCMD), 238 consecutive MDS-RCMD patients were included in this study. Our results showed that SF3B1 mutation in MDS- RCMD patients identifies a homogenous phenotype characterized by homogeneous hematologic features including a high prevalence of erythroid dysplasia and a high proportion of ring sideroblasts, prolonged survival and reduced leukemic transformation.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
ConclusionGenetic abnormalities (FISH/GEP) remain a powerful prognostic indicator for myeloma regardless of MRD status. For newly diagnosed myeloma patients treated with novel triple initial therapy and frontline ASCT, achieving MRD negative status didn’t mitigate poor prognosis outcomes of high-risk MM patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 14 January 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yenny Alejandra Moreno Vanegas, Ridas Juskevicius, Bhagirathbhai Dholaria
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 14 January 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Megan Melody, Najla Al Ali, Ling Zhang, Hanadi Ramadan, Eric Padron, David Sallman, Kendra Sweet, Jeffrey Lancet, Alan List, John M. Bennett, Rami KomrokjiSummaryBackgroundBone marrow fibrosis (BMF), a poor prognostic factor in myelodysplastic syndromes (MDS), in the context of new risk stratifications of MDS has not been fully explored. Here, we examined the relationship between BMF in MDS and survival outcomes and explored the landscape of somatic gene mutations in the setting of BMF.MethodsWe retrospectively evalua...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsT cell exhaustion has been suspected to contribute to poor persistence of CAR T-cells and clinical relapse, which may be overcome by checkpoint inhibition. While the synergy between CAR T-cell therapy and checkpoint inhibition is promising, the interaction may also lead to off-target irAEs. Prospective trials exploring the safety and efficacy of this combination in relapsed/refractory DLBCL are under way.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Minimal residual disease (MRD) is a standard measurement for response assessment in multiple myeloma (MM). Despite new treatments, high-risk MM patients continue to have poor prognosis. We evaluated the impact of MRD- in high vs standard- risk patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Lymphoplasmacytic lymphoma (LPL) with or without Waldenstr ӧm macroglobulinemia (WM) is a rare lymphoproliferative disorder (LPD) characterized by the presence of monoclonal immunoglobulin M (IgM) paraproteinemia and bone marrow (BM) infiltration by small lymphocytes with plasmacytoid or plasma cell differentiation.1 LPL/WM constitutes less than 5% of all non-Hodgkin lymphomas (NHLs) and 1-2% of hematological malignancies.2 Patients with LPL/WM may be initially asymptomatic (smoldering WM) but over the course of their disease they may present with fatigue, shortness of breath, anemia, lymphadenopathy (LAD), splenomegaly a...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
The presence of grade 3 BMF is associated with reduced OS independent from IPSS-R; however, BMF grade did not impact response to hypomethylating agent or lenalidomide treatment. TP53 and SETBP1 mutations occurred with greater frequency among patients with severe fibrosis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: January 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 1Author(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: January 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 1Author(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Bone Graft | Cancer & Oncology | Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Study | Transplants